drugset / Trial / NCT03284268
Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma
NaSingle-groupOpen-labelTreatment
Summary
Phase I study, single site, open label with dose escalation, for evaluate safety and the oncolitic Adenovirus VCN-01 activity in patients with refractory retinoblastoma.
Timeline
- Start
- 2017-09-06
- Primary completion
- 2024-06-14
- Completion
- 2024-06-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zabilugene almadenorepvec | Unknown | 2e+09 unknown | Intravitreal |
| Subject | zabilugene almadenorepvec | Unknown | 2e+10 unknown | Intravitreal |
| Subject | zabilugene almadenorepvec | Unknown | 2e+11 unknown | Intravitreal |